Branded Generics

Global Branded Generics Market to Reach US$328.5 Billion by 2030

The global market for Branded Generics estimated at US$256.3 Billion in the year 2024, is expected to reach US$328.5 Billion by 2030, growing at a CAGR of 4.2% over the analysis period 2024-2030. Anti-Hypertensive Drugs, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$67.5 Billion by the end of the analysis period. Growth in the Alkylating Agents segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$69.8 Billion While China is Forecast to Grow at 7.7% CAGR

The Branded Generics market in the U.S. is estimated at US$69.8 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$67.0 Billion by the year 2030 trailing a CAGR of 7.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global Branded Generics Market - Key Trends & Drivers Summarized

Why Are Branded Generics Gaining Market Traction?

Branded generics are becoming increasingly popular as they offer a cost-effective alternative to branded prescription drugs while maintaining quality and efficacy. These drugs are repackaged and marketed under a brand name, often by the original manufacturer or another pharmaceutical company. With the rising costs of branded medications and the growing need for affordable healthcare, branded generics are filling a crucial gap in the pharmaceutical market. Healthcare providers and patients alike are opting for branded generics due to their reliability, regulatory approvals, and cost benefits. As governments worldwide push for generic drug adoption to lower healthcare expenses, branded generics are expected to witness a steady rise in demand.

How Are Regulations and Market Strategies Shaping the Industry?

The regulatory landscape plays a vital role in the growth of the branded generics market. Many countries have streamlined their drug approval processes to encourage generic drug adoption, making it easier for pharmaceutical companies to introduce branded generics. Patent expirations of blockbuster drugs have also opened opportunities for drugmakers to rebrand generic equivalents, providing an additional revenue stream. Additionally, strategic marketing initiatives, such as physician endorsements, aggressive pricing strategies, and consumer awareness campaigns, are helping pharmaceutical firms expand their branded generics portfolios. With increasing market competition, companies are investing in innovative formulations and biosimilars to differentiate their offerings and gain a competitive edge.

Which Therapeutic Areas Are Driving Branded Generics Adoption?

Branded generics are making significant inroads across multiple therapeutic segments, including cardiovascular diseases, oncology, neurology, and diabetes management. The demand for cost-effective chronic disease treatments is one of the primary drivers of market expansion. In emerging economies, where healthcare infrastructure is still developing, branded generics provide an affordable alternative for long-term disease management. Additionally, biosimilars, a fast-growing segment within branded generics, are revolutionizing treatments for autoimmune disorders and cancer, reducing dependency on expensive biologics. The increasing burden of lifestyle diseases and the need for accessible treatment options are fueling the adoption of branded generics across diverse medical fields.

What Factors Are Driving Market Growth?

The growth in the branded generics market is driven by several factors, including rising healthcare costs, increasing patent expirations, and the expansion of pharmaceutical distribution networks. Governments and insurance companies are actively promoting the use of branded generics to control medication costs and enhance drug accessibility. Additionally, pharmaceutical companies are leveraging digital platforms and e-commerce channels to enhance product availability and consumer outreach. The rise of personalized medicine and targeted therapies is also influencing the development of advanced branded generics with improved efficacy and safety profiles. As the pharmaceutical industry continues to evolve, branded generics are expected to play an integral role in balancing cost efficiency with quality healthcare solutions.

SCOPE OF STUDY:

The report analyzes the Branded Generics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Drug Class (Anti-Hypertensive Drugs, Alkylating Agents, Hormones, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Antimetabolites, Other Drug Classes); Administration Route (Oral Administration, Topical Administration, Parenteral Administration, Other Administration Routes); Distribution Channel (Retail Pharmacy Distribution Channel, Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel); Application (Oncology Application, Cardiovascular Diseases Application, Neurological Diseases Application, Gastrointestinal Diseases Application, Dermatological Diseases Application, Acute and Chronic Pain Application, Other Applications)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• Amneal Pharmaceuticals, Inc.
• Aspen Pharmacare Holdings Limited
• Aurobindo Pharma Ltd.
• Biocon Limited
• Cipla Ltd.
• Dr. Reddy`s Laboratories Ltd.
• Fresenius Kabi AG
• Glenmark Pharmaceuticals Ltd.
• Hikma Pharmaceuticals plc
• Krka, d. d., Novo mesto
• Lupin Limited
• Sandoz Group AG
• Sawai Pharmaceutical Co., Ltd.
• Stada Arzneimittel AG
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Torrent Pharmaceuticals Ltd.
• Towa Pharmaceutical Co., Ltd.
• Viatris Inc.
• Zydus Lifesciences Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.